Response to abatacept is associated with the inhibition of proteasome β1i expression in T cells of patients with rheumatoid arthritis

OBJECTIVE: Abatacept is a biological disease-modifying antirheumatic drug (DMARD) used for the treatment of rheumatoid arthritis (RA) and modulates the costimulatory signal by cluster of differentiation (CD)28:CD80/CD86 interaction required for T cell activation. Since CD28-mediated signalling regul...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghannam, Khetam, Martinez Gamboa, Lorena, Kedor, Claudia, Spengler, Lydia, Kuckelkorn, Ulrike, Häupl, Thomas, Burmester, Gerd, Feist, Eugen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7547540/
https://www.ncbi.nlm.nih.gov/pubmed/32998980
http://dx.doi.org/10.1136/rmdopen-2020-001248

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7547540/
https://www.ncbi.nlm.nih.gov/pubmed/32998980
http://dx.doi.org/10.1136/rmdopen-2020-001248

Ejemplares similares